Leukemia · 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Costa Luciano J, Banerjee Rahul, Mian Hira, Weisel Katja, Bal Susan, Derman Benjamin A, Htut Maung M, Nagarajan Chandramouli, Rodriguez Cesar, Richter Joshua, Frigault Matthew J, Ye Jing C, van de Donk Niels W C J, Voorhees Peter M, Puliafito Benjamin, Bahlis Nizar, Popat Rakesh, Chng Wee Joo, Ho P Joy, Kaur Gurbakhash, Kapoor Prashant, Du Juan, Schjesvold Fredrik, Berdeja Jesus, Einsele Hermann, Cohen Adam D, Mikhael Joseph, Biru Yelak, Rajkumar S Vincent, Lin Yi, Martin Thomas G, Chari Ajai
Аннотация
T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are several products available around the world and several more in development targeting primarily B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GRPC5D). The relatively rapid availability of multiple immunotherapies brings the necessity to understand how a certain agent may affect the safety and efficacy of a subsequent immunotherapy so MM physicians and patients can aim at optimal sequential use of these therapies. The International Myeloma Working Group conveyed panel of experts to review patient and disease-related factors affecting efficacy and safety of immunotherapy, summarize existing information on sequencing therapy and provide a series of core recommendations.